Discontinued OTC asthma med may make comeback

Share this article:

OTC inhaler Primatene Mist officially left the building in August 2013, just over two years after it was banned because the prescription-free asthma inhaler's chlorofluorocarbons violated environmental regulations.

Regulatory Focus reports that the last of the inhalers was officially off the market this summer, but that a Federal Register notice indicates the FDA's Pulmonary-Allergy Drugs Advisory Committee is set to consider an OTC replacement Feb. 25. The new Primatene Mist is currently operating under the name Primatene HFA.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.